Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea
- Written by PR Newswire
YANTAI, China, Feb. 5, 2024 /PRNewswire/ -- Luye Pharma Group has entered into an agreement with Myung In Pharm, granting the latter the exclusive rights to commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea. Developed by Luye Pharma, this drug is used to treat mild to moderate dementia associated with Alzheimer's...














